FDA Reshapes Drug Testing Approach - Takeaways - MDSpire

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

  • By

  • Kathryn Wighton

  • April 20, 2026

  • 2 min

Share

  • 1

    The FDA is implementing a roadmap to reduce animal testing in drug development by 2025, meeting initial milestones.

  • 2

    Alternative methods, such as in vitro systems and computational modeling, are being advanced to improve drug testing accuracy.

  • 3

    Over 90% of drugs deemed safe in animal studies fail during human trials due to safety or efficacy issues.

  • 4

    The FDA has issued guidance to eliminate nonhuman primate testing and reduce horseshoe crab-derived endotoxin testing.

  • 5

    Collaboration with international regulators and NIH supports the FDA's efforts to improve drug safety predictions and reduce animal use.

Original Source(s)

FDA Reshapes Drug Testing Approach

  • by Kathryn Wighton

  • April 20, 2026

Related Content

Narrow DCIS Margins May Not Always Warrant Reexcision

An ancillary analysis found less than 2-percentage-point differences in 10-year recurrence across margin thresholds, with no statistically significant adjusted association.

Immediate Repair Successful After Urethral Injury

Case report described successful immediate reconstruction of a membranous urethral injury recognized during rectal cancer surgery.

More Physicians Enter Politics

Viewpoint explores how more physician-candidates could reshape both public service and public trust in medicine.